We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Astellas Pharma Inc. (ALPMY - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Astellas Pharma Inc. is one of 891 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ALPMY's full-year earnings has moved 14.7% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ALPMY has moved about 23.8% on a year-to-date basis. At the same time, Medical stocks have lost an average of 5.1%. This shows that Astellas Pharma Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Adlai Nortye Ltd. Sponsored ADR (ANL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 745.1%.
For Adlai Nortye Ltd. Sponsored ADR, the consensus EPS estimate for the current year has increased 43.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Astellas Pharma Inc. is a member of the Medical - Drugs industry, which includes 133 individual companies and currently sits at #88 in the Zacks Industry Rank. On average, this group has gained an average of 1.5% so far this year, meaning that ALPMY is performing better in terms of year-to-date returns.
Adlai Nortye Ltd. Sponsored ADR, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 436-stock industry is ranked #148. The industry has moved +2.1% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Astellas Pharma Inc. and Adlai Nortye Ltd. Sponsored ADR as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Astellas Pharma Inc. (ALPMY - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Astellas Pharma Inc. is one of 891 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ALPMY's full-year earnings has moved 14.7% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ALPMY has moved about 23.8% on a year-to-date basis. At the same time, Medical stocks have lost an average of 5.1%. This shows that Astellas Pharma Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Adlai Nortye Ltd. Sponsored ADR (ANL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 745.1%.
For Adlai Nortye Ltd. Sponsored ADR, the consensus EPS estimate for the current year has increased 43.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Astellas Pharma Inc. is a member of the Medical - Drugs industry, which includes 133 individual companies and currently sits at #88 in the Zacks Industry Rank. On average, this group has gained an average of 1.5% so far this year, meaning that ALPMY is performing better in terms of year-to-date returns.
Adlai Nortye Ltd. Sponsored ADR, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 436-stock industry is ranked #148. The industry has moved +2.1% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Astellas Pharma Inc. and Adlai Nortye Ltd. Sponsored ADR as they attempt to continue their solid performance.